LG Life Sciences, Ltd – Product Pipeline Review – H2 2011

LG Life Sciences, Ltd – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “LG Life Sciences, Ltd - Product Pipeline Review - H2 2011” provides data on the LG Life Sciences, Ltd’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, LG Life Sciences, Ltd’s corporate website, SEC filings, investor presentations and featured press releases, both from LG Life Sciences, Ltd and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• LG Life Sciences, Ltd - Brief LG Life Sciences, Ltd overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of LG Life Sciences, Ltd human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of LG Life Sciences, Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the LG Life Sciences, Ltd’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate LG Life Sciences, Ltd’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of LG Life Sciences, Ltd in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the LG Life Sciences, Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with LG Life Sciences, Ltd.
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of LG Life Sciences, Ltd and identify potential opportunities in those areas.

Contents

LG Life Sciences, Ltd Snapshot
LG Life Sciences, Ltd Overview
Key Information
Key Facts
LG Life Sciences, Ltd – Research and Development Overview
Key Therapeutic Areas
LG Life Sciences, Ltd – Pipeline Review
Pipeline Products by Stage of Development
LG Life Sciences, Ltd – Pipeline Products Glance
LG Life Sciences, Ltd – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
LG Life Sciences, Ltd Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
LG Life Sciences, Ltd–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
LG Life Sciences, Ltd – Drug Profiles
Anti-Obesity Drug
  Product Description
  Mechanism of Action
  R&D Progress
Cytopro
  Product Description
  Mechanism of Action
  R&D Progress
DtwP-HB-Hib (Recon) Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
EPO (Espogen)
  Product Description
  Mechanism of Action
  R&D Progress
FAAH Inhibitor
  Product Description
  Mechanism of Action
  R&D Progress
Gemigliptin
  Product Description
  Mechanism of Action
  R&D Progress
Glucokinase Activator
  Product Description
  Mechanism of Action
  R&D Progress
HIB vaccine
  Product Description
  Mechanism of Action
  R&D Progress
HPV vaccine
  Product Description
  Mechanism of Action
  R&D Progress
LB03002
  Product Description
  Mechanism of Action
  R&D Progress
LB80380
  Product Description
  Mechanism of Action
  R&D Progress
LBVH0101
  Product Description
  Mechanism of Action
  R&D Progress
LC350189
  Product Description
  Mechanism of Action
  R&D Progress
Lercanidipine + Valsartan
  Product Description
  Mechanism of Action
  R&D Progress
P2Y12 Inhibitor
  Product Description
  Mechanism of Action
  R&D Progress
PAR-1 Inhibitor
  Product Description
  Mechanism of Action
  R&D Progress
TNFmab
  Product Description
  Mechanism of Action
  R&D Progress
XO Inhibitor
  Product Description
  Mechanism of Action
  R&D Progress
LG Life Sciences, Ltd – Pipeline Analysis
LG Life Sciences, Ltd – Pipeline Products by Therapeutic Class
LG Life Sciences, Ltd - Pipeline Products By Target
LG Life Sciences, Ltd – Pipeline Products by Route of Administration
LG Life Sciences, Ltd – Pipeline Products by Molecule Type
LG Life Sciences, Ltd – Recent Pipeline Updates
LG Life Sciences, Ltd - Dormant Projects
LG Life Sciences, Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 29, 2009: LG Life Sciences Discovers Innovative Necrosis Inhibitors
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency
Apr 26, 2006: Completion of ANA380 Dosing in Phase II Clinical Trial Confirms Robust Activity Against Lamivudine-Resistant Hepatitis B Virus
Apr 18, 2005: Anadys Pharmaceuticals and LG Life Sciences Report Activity Against Lamivudine Resistant Strains in Phase II Clinical Trial of ANA380 for Hepatitis B
Apr 13, 2007: ANA380 Exhibits Activity In Vitro Against Multiple Clinically
Jun 11, 2009: Biopartners And LG Life Sciences Ltd Presents Positive Phase III Results
May 11, 2004: Anadys Pharmaceuticals & LG Life Sciences Announce Completion Phase I/IIa Clinical Trial ANA380 -LB80380- Patients Chronically Infected With Hepatitis B Virus
Jan 08, 2010: LG Life Sciences Receive KFDA Approval For Factive In Otitis Media
Financial Deals Landscape
LG Life Sciences, Ltd, Deals Summary
LG Life Sciences, Ltd, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Green Cross Enters Into Co-Promotion Agreement With LG Life Sciences For Shinbaro
LG Life Sciences Enters Into Co-Development Agreement With Macrogen
LG Life Sciences Enters Into Co-Marketing Agreement With Anteis
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea
Shandong Luye Enters Into An Agreement With LG Life Sciences
ProStrakan Signs An Agreement With LG Life Sciences
LG Life Sciences Enters Into Co-Development Agreement With Institut Pasteur
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea
LG Life Sciences Enters Into Distribution Agreement With Sinovac Biotech
Sinovac Enters Into Co-Marketing Agreement With LG Life Sciences
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea
aRigen pharmaceuticals Enters Into Co-Marketing Agreement With LG Life Sciences
Licensing Agreements
Novavax Enters Into Licensing Agreement With LG Life Sciences
LG Life Sciences Enters Into Licensing Agreement With Nobel Ilac Sanayii ve Ticaret
LG Life Sciences Enters Into Licensing Agreement With Beijing Double-Crane
Gilead Sciences Enters Into Licensing Agreement With LG Life Sciences
Takeda Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences
Depomed Amends Licensing Agreement With LG Life Sciences
Oscient Pharmaceuticals Amends Licensing Agreement With LG Life Sciences
Debiopharm Enters Into Licensing Agreement With LG Life Sciences
Kyorin Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences
Veropharm Enters Into Licensing Agreement With LG Life Sciences For Factive
LG Life Sciences Enters Into Licensing Agreement With Depomed
Anadys Pharmaceuticals Enters Into Co-Development And Licensing Agreement With LG Life Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

LG Life Sciences, Ltd – Pipeline by Therapy Area and Indication, H2 2011
LG Life Sciences, Ltd – Pipeline by Stage of Development, H2 2011
LG Life Sciences, Ltd – Filed, H2 2011
LG Life Sciences, Ltd – Phase III, H2 2011
LG Life Sciences, Ltd - Phase II, H2 2011
LG Life Sciences, Ltd - Phase I, H2 2011
LG Life Sciences, Ltd - Pipeline By Therapeutic Class, H2 2011
LG Life Sciences, Ltd - Pipeline By Target, H2 2011
LG Life Sciences, Ltd – Pipeline By Route of Administration, H2 2011
LG Life Sciences, Ltd – Pipeline By Molecule Type, H2 2011
LG Life Sciences, Ltd – Recent Pipeline Updates, H2 2011
LG Life Sciences, Ltd - Dormant Developmental Projects, 2010
LG Life Sciences, Ltd, Other Locations
LG Life Sciences, Ltd, Subsidiaries
LG Life Sciences, Ltd, Deals Summary
Green Cross Enters Into Co-Promotion Agreement With LG Life Sciences For Shinbaro
LG Life Sciences Enters Into Co-Development Agreement With Macrogen
LG Life Sciences Enters Into Co-Marketing Agreement With Anteis
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea
Shandong Luye Enters Into An Agreement With LG Life Sciences
ProStrakan Signs An Agreement With LG Life Sciences
LG Life Sciences Enters Into Co-Development Agreement With Institut Pasteur
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea
LG Life Sciences Enters Into Distribution Agreement With Sinovac Biotech
Sinovac Enters Into Co-Marketing Agreement With LG Life Sciences
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea
aRigen pharmaceuticals Enters Into Co-Marketing Agreement With LG Life Sciences
Novavax Enters Into Licensing Agreement With LG Life Sciences
LG Life Sciences Enters Into Licensing Agreement With Nobel Ilac Sanayii ve Ticaret
LG Life Sciences Enters Into Licensing Agreement With Beijing Double-Crane
Gilead Sciences Enters Into Licensing Agreement With LG Life Sciences
Takeda Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences
Depomed Amends Licensing Agreement With LG Life Sciences
Oscient Pharmaceuticals Amends Licensing Agreement With LG Life Sciences
Debiopharm Enters Into Licensing Agreement With LG Life Sciences
Kyorin Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences
Veropharm Enters Into Licensing Agreement With LG Life Sciences For Factive
LG Life Sciences Enters Into Licensing Agreement With Depomed
Anadys Pharmaceuticals Enters Into Co-Development And Licensing Agreement With LG Life Sciences

LIST OF FIGURES

LG Life Sciences, Ltd – Pipeline by Therapy Area and Indication, H2 2011
LG Life Sciences, Ltd – Pipeline by Stage of Development, H2 2011
LG Life Sciences, Ltd – Pipeline By Therapeutic Class, H2 2011
LG Life Sciences, Ltd - Pipeline By Target, H2 2011
LG Life Sciences, Ltd – Pipeline By Route of Administration, H2 2011
LG Life Sciences, Ltd – Pipeline By Molecule Type, H2 2011 Skip to top